Laboratory of Cancer Genetics, Department of Clinical Genetics and Biocenter Oulu, Oulu University Hospital, University of Oulu, PO Box 5000, 90014 Oulu, Finland.
Fam Cancer. 2010 Dec;9(4):537-40. doi: 10.1007/s10689-010-9360-7.
In search for susceptibility genes that could explain an additional portion of familial breast cancer clustering in Finland, we set out to evaluate the presence of large genomic rearrangements in two candidate genes, BRIP1 and CHK1. BRIP1 is a BRCA1 associated protein that is mutated in a fraction of familial breast cancer and Fanconi anemia cases. To date, the role of large BRIP1 deletions in breast cancer susceptibility is not well-characterized. CHK1 is a critical maintainer of cell cycle checkpoints and genomic stability, and is also involved in the BRCA1 and FA protein signalling pathways. Although CHK1 is a very important protein for cell cycle and DNA integrity maintenance control, no mutations in this gene has yet been associated with predisposition to cancer. For the present study, blood DNA from affected index persons of 111 Northern Finnish breast cancer families was assessed for possible constitutional exonic deletions or amplifications in the BRIP1 and CHK1 genes by using the multiplex ligation-dependent probe amplification method. Our results showed that exonic deletions or amplifications affecting the BRIP1 and CHK1 genes seem not to contribute to hereditary breast cancer susceptibility in the Finnish population. To our knowledge, this is the first attempt to determine the existence of large CHK1 deletions in familial breast cancer or in any disease with a hereditary background.
为了寻找能够解释芬兰家族性乳腺癌聚集的其他易感基因,我们着手评估两个候选基因 BRIP1 和 CHK1 中是否存在大片段基因组重排。BRIP1 是 BRCA1 相关蛋白,在一部分家族性乳腺癌和范可尼贫血病例中发生突变。迄今为止,大片段 BRIP1 缺失在乳腺癌易感性中的作用尚未得到很好的描述。CHK1 是细胞周期检查点和基因组稳定性的关键维持者,也参与 BRCA1 和 FA 蛋白信号通路。虽然 CHK1 对于细胞周期和 DNA 完整性维持控制非常重要,但尚未发现该基因的突变与癌症易感性有关。在本研究中,使用多重连接依赖性探针扩增方法评估了 111 个来自芬兰北部的乳腺癌家族的受累指数个体的血液 DNA 中 BRIP1 和 CHK1 基因是否存在可能的外显子缺失或扩增。我们的结果表明,影响 BRIP1 和 CHK1 基因的外显子缺失或扩增似乎不会导致芬兰人群的遗传性乳腺癌易感性。据我们所知,这是首次尝试确定大片段 CHK1 缺失是否存在于家族性乳腺癌或任何具有遗传背景的疾病中。